Huldrych Günthard
Adverse events of raltegravir and dolutegravir
Elzi L, Battegay M, Bernasconi E, Günthard H, Vernazza P, Calmy A, Cavassini M, Furrer H, Erb S. Adverse events of raltegravir and dolutegravir. AIDS 2017; 31:1853-1858.
Aug 24, 2017Adverse events of raltegravir and dolutegravir
Aug 24, 2017AIDS 2017; 31:1853-1858
Elzi Luigia, Battegay Manuel, Bernasconi Enos, Günthard Huldrych, Vernazza Pietro, Calmy Alexandra, Cavassini Matthias, Furrer Hansjakob, Erb Stefan
Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study
Wolbers M, Bucher H, Günthard H, Yerly S, Battegay M, Bernasconi E, Vernazza P, Cavassini M, Furrer H, Hirschel B, von Wyl V, Opravil M, Swiss HIV Cohort Study. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. AIDS (London, England) 2007; 21:2201-7.
Oct 18, 2007Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study
Oct 18, 2007AIDS (London, England) 2007; 21:2201-7
Wolbers Marcel, Bucher Heiner C, Günthard Huldrych, Yerly Sabine, Battegay Manuel, Bernasconi Enos, Vernazza Pietro, Cavassini Matthias, Furrer Hansjakob, Hirschel Bernard, von Wyl Viktor, Opravil Milos, Swiss HIV Cohort Study
HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
Schüpbach J, Hirschel B, Bernasconi E, Vernazza P, Furrer H, Battegay M, Perrin L, Yerly S, Tomasik Z, Böni J, Fischer M, Joos B, Günthard H, Swiss HIV Cohort Study. HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. Journal of acquired immune deficiency syndromes (1999) 2005; 40:250-6.
Nov 1, 2005HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
Nov 1, 2005Journal of acquired immune deficiency syndromes (1999) 2005; 40:250-6
Schüpbach Jörg, Hirschel Bernard, Bernasconi Enos, Vernazza Pietro, Furrer Hansjakob, Battegay Manuel, Perrin Luc, Yerly Sabine, Tomasik Zuzana, Böni Jürg, Fischer Marek, Joos Beda, Günthard Huldrych, Swiss HIV Cohort Study
A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART
Fagard C, Hirschel B, Perrin L, Perneger T, Oxenius A, Ebnöther C, Telenti A, Bernasconi E, Vernazza P, Egger M, Hirsch H, Günthard H, Le Braz M, Swiss HIV Cohort Study. A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART. AIDS (London, England) 2003; 17:1487-92.
Jul 4, 2003A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART
Jul 4, 2003AIDS (London, England) 2003; 17:1487-92
Fagard Catherine, Hirschel Bernard, Perrin Luc, Perneger Thomas, Oxenius Annette, Ebnöther Corinna, Telenti Amalio, Bernasconi Enos, Vernazza Pietro, Egger Martin, Hirsch Hans H, Günthard Huldrych, Le Braz Michelle, Swiss HIV Cohort Study
A prospective trial of structured treatment interruptions in human immunodeficiency virus infection
Fagard C, Price D, Dawson S, Klimkait T, Perneger T, McLean A, Clotet B, Gatell J, Perrin L, Plana M, Phillips R, Hirschel B, Yerly S, Leduc D, Oxenius A, Günthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Swiss HIV Cohort Study. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Archives of internal medicine 2003; 163:1220-6.
May 26, 2003A prospective trial of structured treatment interruptions in human immunodeficiency virus infection
May 26, 2003Archives of internal medicine 2003; 163:1220-6
Fagard Catherine, Price David, Dawson Sara J, Klimkait Thomas, Perneger Thomas V, McLean Angela, Clotet Bonaventura, Gatell Jose M, Perrin Luc, Plana Montserrat, Phillips Rodney, Hirschel Bernard, Yerly Sabine, Leduc Dominique, Oxenius Annette, Günthard Huldrych, Garcia Felipe, Le Braz Michelle, Mestre Gabriel, Battegay Manuel, Furrer Hansjakob, Vernazza Pietro, Bernasconi Enos, Telenti Amalio, Weber Rainer, Swiss HIV Cohort Study
A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection
Opravil M, Perrin L, Weber R, Howe C, Günthard H, Ledergerber B, Battegay M, Bernasconi E, Vernazza P, Fischer M, Bisset L, Yerly S, Chave J, Furrer H, Lazzarin A, Hirschel B, Swiss HIV Cohort Study. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. The Journal of infectious diseases 2002; 185:1251-60.
May 1, 2002A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection
May 1, 2002The Journal of infectious diseases 2002; 185:1251-60
Opravil Milos, Perrin Luc, Weber Rainer, Howe Colin, Günthard Huldrych, Ledergerber Bruno, Battegay Manuel, Bernasconi Enos, Vernazza Pietro, Fischer Marek, Bisset Leslie R, Yerly Sabine, Chave Jean-Philippe, Furrer Hansjakob, Lazzarin Adriano, Hirschel Bernard, Swiss HIV Cohort Study